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Intratumoral interleukin-6 predicts ascites
formation in patients with epithelial ovarian
cancer: A potential tool for close monitoring
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Abstract
Background: The implication of IL-6 in the pathogenesis of epithelial ovarian cancer (EOC) is well documented.
Accordingly, the clinicopathological significance of this cytokine in patients’ ascites fluid or serum has largely been
investigated. Since the main source of IL-6 secreted into the biological fluids is the tumor tissue, this study was
designed to investigate the status and possible clinical relevance of the IL-6 expression in an array of EOC tissue
specimens.
Methods: Tissue samples obtained from ninety-eight consecutive patients with EOC were studied using
immunohistochemistry. Clinicopathological characteristics and treatment related factors were collected from
patient files. The relationship between the expression of the protein of interest and the study endpoints of
disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. For evaluating the
predictive value of IL-6, logistic regression and cox proportional hazards models were employed.
Results: An upregulation of IL-6 expression was observed in EOC tissues as compared with the normal samples
(p < 0.0001). As regards the clinical relevance, IL-6 failed to predict OS, DFS and response to the platinum-based
chemotherapy in EOC patients. In multivariate analysis, however, IL-6 was identified as an independent predictive
factor for the development of post-treatment ascites (p:0.033).
Conclusions: Having the capability to predict the ascites formation, IL-6 might serve as a biomarker and a useful
tool in EOC for monitoring purposes. IL-6 targeting for the prevention of the ascites development is a potential
avenue for further investigation.
Keywords: Ascites, Chemorefractoriness, Disease free survival, Epithelial ovarian cancer, Interleukin-6, Overall
survival
Background
Interleukin-6 (IL-6) is a classic pro-inflammatory cyto-
kine associated with a variety of pathological conditions,
including cancer. Evidence supports the role of IL-6 in
the pathophysiology of epithelial ovarian cancer (EOC)
where the presence of an immunosuppressive network
protecting tumor from immune system is also involved
in EOC growth and progression [1–3]. While contribut-
ing to the follicle development in normal ovaries and the
regulation of chronic inflammation, IL-6 can be involved
in the provision of a cellular microenvironment benefi-
cial to cancer cell growth, proliferation, migration and
survival. This can result from direct effects on tumor
cell biology along with the regulation of the immune
system components [4, 5]. In vitro studies have con-
firmed the production of IL-6 by normal and neoplastic
ovarian epithelium [6, 7]. The association of IL-6 with
EOC carcinogenesis and progression [8], as well as with
the enhancement of EOC cell survival, resistance to
chemotherapy [9] and invasiveness [10] has also been
reported.
In the present study, we investigated the expression
status of the intratumoral IL-6 in EOC tissue samples
compared with normal ovarian tissue and evaluated a
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possible clinical relevance with regard to survival, re-
sponse to the platinum-based chemotherapy and ascites
formation. As a result, we observed a significant upregu-
lation of IL-6 in the EOC tissue. Moreover, we identified
IL-6 expression status of EOC tumor as an independent
predictive biomarker for ascites formation in patients
receiving adjuvant carbotaxol treatment.
Patients and methods
Clinical cases and surgical samples
Initially, institutional review board approval for this
analysis was obtained from South Eastern Sydney and
Illawarra Area Health Service Human Research Ethics
Committee-Central Network (EC00135). Upon giving
informed written consents, ninety-eight consecutive
patients with primary epithelial ovarian cancer who had
undergone standard surgical procedure (staging laparot-
omy/cytoreductive surgery) and adjuvant systemic chemo-
therapy (paclitaxel + carboplatin) between January 2001
and December 2012 at two specialized centers (St. George
Hospital; St George Private Hospital, Sydney, Australia)
were included in the study. A confirmatory review of
pathology was performed. Ovarian neoplasms were
histologically classified according to the World Health
Organization (WHO) classification system [11]. The
final staging of the disease was determined on the basis of
a combination of surgical and pathological findings in ac-
cord with the Federation of Gynecology and Obstetrics
(FIGO) guidelines [12]. Clinicopathological characteristics
of the participants are shown in Table 1.
Immunohistochemical staining
For immunohistochemical study, five-micrometer sec-
tions were prepared from the paraffin blocks of the pa-
tients and immunostained as described previously [13].
Briefly, the sections were deparaffinized and incubated
with 3 % hydrogen peroxide and DAKO blocking buffer,
subsequently. This was followed by overnight incubation
at 4 °C with mouse monoclonal primary antibody (Santa
Cruz) and then with appropriate secondary antibody
using EnVision Plus kit (DAKO). The sections were then
counterstained with hematoxylin. Tonsil tissue was used
as the positive control. As regards the negative control,
the same tissue as our positive control was used but the
primary antibodies were replaced with the primary anti-
body diluents.
Immunohistochemical scoring
To evaluate the staining of the epithelial cells, a semi-
quantitative scoring method was performed according to
Mattern et al. and Terris et al. [14, 15]. This scoring
method enables the determination of both the intensity
of the immunosignal and the percentage of cells showing
positive staining. The percentage of positive cells was
scored as: no positive cells (0); 1–25 % (1); 26–50 % (2);
and 50 % > (3). The intensity of the staining was scored
as: no staining (0); weak (1); moderate (2); strong (3).
Following the evaluation by two observers blinded to
patient outcome, the immunohistochemical score was
calculated as follows, yielding a range of values between
0 and 9: immunohistochemical score = [percentage of
positive cells] × [intensity of staining].
Statistical analysis
All statistical analyses were conducted using the statis-
tical package SPSS, version 22 (SPSS Inc., USA). Stu-
dent t-test was used for comparing the actual difference
between two means. Spearman correlation coefficient
testing was performed to evaluate the associations be-
tween the clinicopathological parameters and the expres-
sion of IL-6. The binary cut-off point was identified using
the Classification and Regression Tree (CART) algorithm.
According to the cut-off point determined, the immuno-
histochemical scores were classified as either low (score ≤
3.5) or high (score > 3.5). The relationship between the IL-
6 expression and the study endpoints of disease-free
survival (DFS) and overall survival (OS) were individually
analyzed using the Kaplan-Meier method. Univariate and
multivariate logistic regression analyses were conducted
to ascertain the effect of the studied cytokine and other
clinicopathological variables on the likelihood of the
development of post-treatment ascites or chemotherapy
Table 1 Clinicopathological characteristics of the participants
Characteristic Categorization Patients (n = 98)
Age (years) Range: 35–84 ≤50 16
Median: 62 >50 82







FIGO stage I-II 14
III-IV 84








post-treatment ascites Yes 40
No 58
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refractory disease. A p value of < 0.05 was considered sta-
tistically significant for all analyses.
Results
EOC tumors express higher levels of IL-6
Comparing the expression status of IL-6 in EOC tissues
with that in normal samples, we found significantly higher
levels of the IL-6 expression in tumor tissues (p < 0.0001).
Mean expression scores were 3.35 ± 0.15 and 1.15 ± 0.15
for tumor and normal biopsies, respectively. When the IL-
6 immunohistochemical scores of matched normal and
cancer tissues were compared, we observed higher levels
of the IL-6 expression in seventy-five percent of tumor
tissues (Fig. 1).
IL-6 predicts development of post-treatment ascites
In our cohort, while 35 cases had no history of ascites
either at the time of diagnosis or after treatment, ascites
was present in 63 patients. Mean IL-6 expression scores in
the ascites group (3.59 ± 0.19) were significantly higher
than those in the non-ascites group (2.91 ± 0.24, p:0.039).
Subgroup analysis did not indicate a statistically signifi-
cant difference in mean IL-6 expression scores between
patients who had ascites at the time of diagnosis (3.56
± 0.22) and those without ascites (3.11 ± 0.21, p:0.154).
On the other hand, the comparison of mean IL-6 ex-
pression scores between patients who did and did not
develop ascites after treatment (3.85 ± 0.26 and 3.00 ±
0.18, respectively) revealed significantly higher levels of
IL-6 expression in the ascites positive group (p:0.007).
When the association between the expression of IL-6
and the history of ascites was evaluated, a direct signifi-
cant correlation was found between the IL-6 expression
and post-treatment ascites formation (p:0.034, correl-
ation coefficient = 0.214).
The predictive value of IL-6 expression with regard to
the development of post-treatment ascites was further
evaluated employing logistic regression analysis. Univari-
ate test revealed the significance of the IL-6 expression
for predicting the development of post-treatment ascites
Fig. 1 Immunohistochemical analysis of IL-6 expression in human epithelial ovarian cancer (EOC) tissue Representative micrographs show high
(A) and low (B) levels of the immunohistochemical expression of IL-6 in the high-grade serous EOC tissue (magnification = 40x) (a) represents the
negative control. Graphs (C) and (D) demonstrate the upregulation of IL-6 in EOC as compared with the normal ovarian tissue. Data are presented
as mean expression score ± SE (C) and maximum and minimum expression score (D). Significant values (<0.05) are marked by asterisks. Graph (E)
indicates the percentage of cases with higher (T > N), lower (T < N) or equal (T = N) intratumoral levels of IL-6 when the protein expressions in tumoral
and matched normal ovarian tissues were compared. Graph (F) shows the mean expression scores of IL-6 in different subgroups of EOC as mean ex-
pression score ± SE. Graph (G) depicts maximum and minimum expression scores of IL-6 in different subgroups of EOC. HGS: high grade serous; LGS:
low grade serous; M: mucinous; HGE: high grade endometrioid; LGE: low grade endometrioid; C: clear cell; O: others. Magnification = 40x
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(HR = 0.39; 95 % CI, 0.16-0.94; p 0.036). Stage (HR = 0.08;
95 % CI, 0.01–0.67; p:0.020), ascites at diagnosis (HR =
0.23; 95 % CI, 0.09–0.55; p:0.001) and refractory disease
(HR = 0.15; 95 % CI, 0.05–0.46; p:0.001) also appeared
to be of predicting value among other clinicopathologi-
cal features. In multivariate logistic regression analysis,
IL-6 (HR = 0.31; 95 % CI, 0.10–0.91; p:0.033), ascites at
diagnosis (HR = 0.22; 95 % CI, 0.07–0.66; p:0.007) and
refractory disease (HR = 0.09; 95 % CI, 0.02–0.36;
p:0.001) retained their values as independent predictors
of post-treatment ascites in EOC patients whereas stage
(p:0 .075) failed to show an independent predictive
value.
IL-6 has no predictive value for overall survival and
disease free survival
In the statistical analysis of overall survival (OS), the dif-
ference in median OS of IL-6 high- and low-expressing
groups (3.8 and 3.9 years, respectively) as well as in mean
OS of these two groups (4.7 and 5.3 years, respectively)
was not statistically significant (p:0.646). With respect to
disease free survival (DFS) of IL-6 high- and low-
expressing groups, there was no statistically meaningful
difference (p:0.30) between the median (22 vs 30 months,
respectively) or mean values (41.5 vs 50 months, respect-
ively) of the two groups, either. Cox analysis of the results
consistently failed to show a predictive value for IL-6 with
regard to survival (OS, p:0.646; DFS, p:0.301).
IL-6 does not predict platinum-based refractory disease
Finally, we investigated whether the expression status of
IL-6 in surgical specimens has the potential to predict
response to the platinum-based chemotherapy. When
patients who later showed resistance to carbotaxol
chemotherapy were accordingly compared with those
who remained sensitive to the same regimens, mean
IL-6 expression scores of the refractory (3.19) and sen-
sitive (3.39) groups turned out to be similar (p:0.605).
Our logistic regression analysis consistently demon-
strated that IL-6 expression fails to predict response to
the platinum-based treatment (p:0.760).
Discussion
IL-6 is known as a pleotropic cytokine implicated in
EOC carcinogenesis. It influences EOC growth and de-
velopment through direct and indirect effects on tumor
cells or their microenvironment, respectively [4, 5]. As
such, IL-6 has been indicated to promote EOC cell pro-
liferation, migration, invasion, survival and resistance to
chemotherapeutic agents [9, 10, 16]. Reports show that
IL-6 contributes to the development of EOC-induced
malignant ascites [8]. Here, we demonstrated that IL-6
was expressed at higher levels in human EOC tissues
than in normal ovarian tissues. In agreement, increased
tumoral expression [17] and high serum [18, 19] or
ascetic [20] levels of IL-6 have been reported in patients
with EOC. Accordingly, clinicopathological relevance of
intratumoral, serum or ascitic IL-6 in EOC has been
investigated [18–25]. Plewka et al. [26] observed that
malignant serous tumors had higher expression levels of
IL-6 as compared with serous borderline and benign
lesions. Guo et al. [27] reported a significant difference
in immunohistochemical expressions of IL-6 among the
metastatic, drug-resistant recurrent tumors, and matched
primary tumors, with more staining density and positivity
observed in the drug-resistant and metastatic tumors. In
another study by Coward et al. [28], intensity of IL-6 stain-
ing in malignant cells was found to be significantly associ-
ated with poor prognosis. Similarly, a link between high
levels of serum or ascitic IL-6 and unfavorable clinical
outcome has been reported. In this regard, serum IL-6 has
shown significant association with tumor burden, clinical
disease status, and survival [21, 22], as well as prognostic
value [25], in EOC. In a study by Scambia et al. [29],
higher levels of serum IL-6 was found in patients unre-
sponsive to chemotherapy. In line with these findings, Co-
hen et al. [30] found that cisplatin treatment of EOC cells
upregulated IL-6, and IL-6 inhibition, on the other hand,
resulted in significant sensitization to cisplatin, suggesting
that IL-6 could contribute to the induction of platinum
resistance in EOC. In agreement, Wang et al. found
that both exogenous and endogenous IL-6 could induce
cisplatin and paclitaxel resistance in vitro via increased
expression of both multidrug resistance-related genes
and apoptosis inhibitory proteins, as well as activation
of extracellular signal-regulated kinases (ERK) and Akt
signaling [9]. They also demonstrated that IL-6 might
contribute to the refractoriness of EOC to tamoxifen
[31]. In our study, however, intratumoral IL-6 showed
neither dependent nor independent predicting value for
OS, DFS or response to the platinum-based chemother-
apy. In line with our results, Plante el al [20] indicated
that serum and ascites IL-6 levels did not correlate
statistically with OS. In contrast to our observation,
where almost equal intratumoral IL-6 levels were detected
in platinum-based resistant and sensitive cases, they
reported lower ascitic IL-6 in patients who responded to
chemotherapy, although the difference was not found to
be statistically significant.
In EOC, ascites is present in at least one third of patients
and is believed to contribute to the spread of cancer to sec-
ondary sites [32], as well as to peritoneal dissemination
[33]. Interestingly, the predictive value of IL-6 for the devel-
opment of post-treatment ascites was observed in the
present study. In line with our findings, Plante el al [20]
reported a direct association between ascitic IL-6 and asci-
tes volume. In agreement, Lo et al. [8] described an IL-6
trans-signaling pathway in formation and progression of
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ascites in EOC wherein IL-6 and its soluble IL-6 receptor
(IL-6Rα) serve as an important regulator of endothelial cell
survival, migration, and integrity, and IL-6 trans-signaling
on endothelial cells prevents chemotherapy-induced apop-
tosis, induces endothelial hyperpermeability, and increases
transendothelial migration of ovarian cancer cells, contrib-
uting to ascites formation and tumor progression.
Future clinical investigations are needed to establish
improved clinical evidence to guide patient care in EOC.
With respect to the results from the present study, these
investigations could be developed at two levels: 1) the
assessment of the effectiveness of IL-6 as a tool for post-
treatment monitoring of EOC patients, alone or in com-
bination with current biomarkers in use; 2) the evaluation
of IL-6 as a potential target in the treatment of EOC. With
regard to its value as a potential target for developing novel
treatment strategies, our laboratory has previously studied
the inhibitory effects of minocycline on IL-6 production in
EOC. It was shown in in vivo models of EOC that orally
administered minocycline was highly effective in decreas-
ing tumor burden and suppressing ovarian cancer-induced
malignant ascites by targeting IL-6 [34].
Conclusions
Here, we report the upregulation of IL-6 in EOC, with
predictive value for development of ascites following the
platinum-based treatment. In keeping with results from
previous studies, our findings highlight the role of this
cytokine in EOC patients which needs to be further ex-
plored in future research.
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